*EpidStrategies, a Division of ToxStrategies, Inc., Katy, TX

†Center for Observational Research, Amgen Inc., Thousand Oaks, CA

‡Department of Medical Affairs, Amgen Inc., Thousand Oaks, CA

§University of Pennsylvania, Pennsylvania Hospital, Philadelphia, PA

The data sets generated and analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

This study was funded by Amgen Inc., Thousand Oaks, CA.

G.N. is an employee of EpidStrategies, which has received research funding from Amgen Inc. R.K.H., J.S. and H.S. are employees of, and hold stock in, Amgen Inc. K.B.C., B.C., and V.J.D.S.B. were employees and stakeholders of Amgen Inc. during the course of this study. D.H. declares no conflict of interest.

Correspondence: Jennifer Schenfeld, MPH, Center for Observational Research, Amgen Inc., Thousand Oaks 91320, CA. E-mail: [email protected].

Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, www.amjclinicaloncology.com.